Compare Stitch Fix Inc (SFIX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs TransMedics Group Inc — how do they compare? Stitch Fix Inc trades at $3.94 (market cap $520.36M), while TransMedics Group Inc trades at $73.5 (market cap $2.54B). The key difference: TransMedics Group Inc is far larger — about 4.9× Stitch Fix Inc's market cap, and Stitch Fix Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SFIX | TMDX | |
|---|---|---|
Market Cap | $520.36M | $2.54B |
Sector | Consumer Cyclical | Technology |
52-Week High | $5.83 | $150.42 |
52-Week Low | $3.06 | $61.99 |
Enterprise Value | $408.08M | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $3.84, up 1.32% today, showing signs of stabilization after a challenging period. The stock exhibits a bullish technical signal with improving fundamentals, including narrowing losses and a debt-free balance sheet. Recent quarters show earnings beats, with Q1 2026 actual EPS of -$0.01 beating expectations of -$0.06. Revenue remains stable at $1.27 billion for 2025, while net losses have decreased significantly from -$207 million in 2022 to -$28.74 million in 2025. AI-driven personalization initiatives and active client growth are key positive developments.
The outlook for SFIX is cautiously optimistic as the company's turnaround gains traction. Investment opportunities include potential upside to the $4.75 consensus price target, representing 24% upside, and continued margin improvement. Risks include persistent net losses, competitive pressures in online retail, and sensitivity to consumer spending trends. The stock's low P/S ratio of 0.39 suggests undervaluation if the recovery continues, but execution risks remain substantial.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
